Key result
Low-dose rt-PA significantly lowers PASP at 24 hours vs. anticoagulation alone in intermediate-risk PE.
Why the study?
The efficacy and safety of initial thrombolysis by recombinant tissue-type plasminogen activator compared with anticoagulant therapy in acute intermediate-risk pulmonary embolism patients was uncertain.
Does low dose rt-PA improve right ventricular parameters and clinical outcomes compared to LMWH in patients with acute intermediate-risk pulmonary embolism?
RCT (n=66)
Open-label
Envelope randomization
No
Does low dose rt-PA improve right ventricular parameters and clinical outcomes compared to LMWH in patients with acute intermediate-risk pulmonary embolism?
Low-dose rt-PA rapidly improves right ventricular hemodynamics and reduces hemodynamic decompensation compared to LMWH in acute intermediate-risk pulmonary embolism, though it increases minor bleeding.
Answers are grounded in this paper and cite their sources.
Supports low-dose rt-PA for faster RV hemodynamic recovery in intermediate-risk PE; extends RCT evidence beyond standard anticoagulation.
OBJECTIVES: To investigate the efficacy and safety of initial thrombolysis by recombinant tissue-type plasminogen activator (rt-PA) in compared with anticoagulant therapy in patients with acute intermediate-risk pulmonary embolism (PE). Methods: Sixty-six patients with acute intermediate-risk PE were randomly assigned to receive rt-PA or LMWH between June 2014 and June 2017 in our department. We obtained information regarding the difference in the right ventricle/left ventricle (RV/LV) ratio, pulmonary artery systolic pressure (PASP), clinical symptoms improvement, PE-related mortality, hemodynamic decompensation, recurrent PE, and major and minor bleeding. Results: In the rt-PA group, the mean PASP was reduced from 52.0±12.2 at baseline to 34.8±9.4 (p less than 0.001) and the mean RV/LV ratio was reduced from 1.26±0.22 at baseline to 0.96±0.18 (p less than 0.001) at 24 hours. In the LMWH group, the mean PASP was 53.4±12.8 at baseline and 48.5±11.9 at 24 hours (p=0.11), and the mean RV/LV ratio was 1.22±0.19 at baseline and 1.17±0.21 at 24 hours (p=0.31). In comparison with the LMWH group, there was a significant reduction in PASP and an improvement in the symptom severity in the rt-PA group. At 90 days, there was no difference in mortality, recurrent venous thromboembolism and major bleeding as a safety outcome, but increased minor bleeding and decreased hemodynamic decompensation occurred in the rt-PA group. Conclusions: In patients with acute intermediate-risk PE, low dose thrombolytic therapy is considered safe and effective, it can be recommended as an alternative option in clinical treatment.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2018) conducted an RCT in Acute intermediate-risk pulmonary embolism (n=66). Recombinant tissue-type plasminogen activator (rt-PA) vs. Low-molecular-weight heparin (LMWH) alone was evaluated on Mean reduction in pulmonary artery systolic pressure (PASP) from baseline to 24 hours (p=<0.001). Low dose recombinant tissue-type plasminogen activator reduced pulmonary artery systolic pressure at 24 hours compared to anticoagulation alone in patients with acute intermediate-risk pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: